More SEC Filings
View Older Stories View Newer Stories-
Form 424B2 JPMORGAN CHASE & CO
-
Form D PXES AU PTY LTD
-
Form FWP HSBC USA INC /MD/ Filed by: HSBC USA INC /MD/
-
Form 497 BlackRock ETF Trust
-
Form D KI-0511 Fund I, a series
-
Form D B1 a Series of AF1 Globa
-
Form D CYBIN INC.
-
Form D/A RI-0416 Fund I, a series
-
Form D AS-1204 Fund II, a serie
-
Form FWP JPMORGAN CHASE & CO Filed by: JPMORGAN CHASE & CO
-
Form 15-12G Sigyn Therapeutics, Inc.
-
Form FWP JPMorgan Chase Financial Filed by: JPMorgan Chase Financial Co. LLC
-
Form FWP HSBC USA INC /MD/ Filed by: HSBC USA INC /MD/
-
Form 424B2 Nomura America Finance,
-
Form 20-F Alpha Compute Corp For: Mar 31
-
Form 8-K International Stem Cell For: Jul 10
-
Form 424B2 JPMORGAN CHASE & CO
-
Form 424B2 BARCLAYS BANK PLC
-
Form FWP GS Finance Corp. Filed by: GS Finance Corp.
-
Form D Poly2, a series of Sandl
-
Form FWP BARCLAYS BANK PLC Filed by: BARCLAYS BANK PLC
-
Form N-PX DARLINGTON PARTNERS CAPI For: Jun 30
-
Form D Schilling Capital Ventur
-
Form S-8 POS CATALYST PHARMACEUTICALS
-
Form D OS Therapies Inc
-
Form 1-SA Frontieras North America For: Mar 31
-
Form D TCV Global Growth XIII
-
Form 13F-HR White & Co Financial For: Jun 30
-
Form 8-K Inotiv, Inc. For: Jul 14
-
Form D TCV Global Growth XIII
-
Form 10-K/A AIxCrypto Holdings, Inc. For: Dec 31
-
Form FWP GOLDMAN SACHS GROUP INC Filed by: GOLDMAN SACHS GROUP INC
-
Form D RS2 Healthcare Fund I,
-
Form S-8 POS CATALYST PHARMACEUTICALS
-
Form D CCREP F1 LLC
-
Form S-8 POS CATALYST PHARMACEUTICALS
-
Form S-8 POS CATALYST PHARMACEUTICALS
-
Form 13F-HR First Nebraska Trust Co For: Sep 30
-
Form D Northwind Partners LLC
-
Form S-8 POS CATALYST PHARMACEUTICALS
-
Form D TCV Global Growth XIII
-
Form 10-K Chi Special Acquisition For: Mar 31
-
Form S-8 POS CATALYST PHARMACEUTICALS
-
Form D TCV Global Growth XIII
-
Form D AU-1009 Fund II, a serie
-
Form S-8 POS CATALYST PHARMACEUTICALS
-
Form 424B2 BARCLAYS BANK PLC
-
Form S-8 POS CATALYST PHARMACEUTICALS
-
Form 424B2 BARCLAYS BANK PLC
-
Form D TCV Global Growth XIII,

